Compass Therapeutics, Inc. (CMPX)

Market Cap	209.82M
Revenue (ttm)	850,000
Net Income (ttm)	-47.76M
Shares Out	137.59M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	177,164
Open	1.420
Previous Close	1.380
Day's Range	1.410 - 1.550
52-Week Range	0.765 - 2.340
Beta	0.73
Analysts	Strong Buy
Price Target	13.75 (+801.64%)
Earnings Date	Nov 12, 2024

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPX
• Website: https://www.compasstherapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price forecast is $13.75, which is an increase of 801.64% from the latest price.

Price Target

$13.75

(801.64% upside)

Analyst Consensus: Strong Buy